Ownership history in FEDERATED HERMES, INC. Β· 13 quarters on record
This page tracks every 13F SEC filing in which FEDERATED HERMES, INC. reported a position in CABALETTA BIO INC (CABA). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π FEDERATED HERMES, INC. outperformed the S&P 500 by +524.7% annually on this CABA position. Timing score: 42% (5/12 decisions correct). Average cost basis: $1.79. Maximum drawdown during holding period: β93.9%.
π₯ Exceptional β beat the S&P 500 by 524.7% per year on this position.
12 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
5 of 12 add/trim decisions correct
Best entry: $0.65 (2022 Q3) Β· Worst: $22.70 (2023 Q4)
πͺ Held through 2 major drawdowns (>20%).
9 adds Β· 4 trims. Bought during 6 of 6 down-price quarters. π More buys than sells across the holding period.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.0% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size